Board meeting

18 September 2025

Medicines data: NICE approvals and availability in England

Purpose of paper

For discussion

Board action required

The Board is asked to review the report.

Brief summary

This update for information provides an analysis of availability of branded medicines in England. This includes NICE domestic performance over time and in relation to European peers.

These data provide an important baseline against which we can understand any change in medicines access in the future.

Board sponsor

Sam Roberts, Chief Executive